Skip to main content
Link Pharma Chem Ltd. logo

Link Pharma Chem Ltd. — Investor Relations & Filings

Ticker · 524748 ISIN · INE302F01011 LEI · 335800FO4ZLDW7GZEJ55 BSE.NS Manufacturing
Open in API
Filings indexed 8 across all filing types
Latest filing 2026-05-23 Report Publication Anno…
Country IN India
Listing BSE.NS 524748

About Link Pharma Chem Ltd.

https://linkpharmachem.co.in/

Link Pharma Chem Ltd. specializes in the manufacturing of high-quality pharmaceutical intermediates and specialty chemicals. The company focuses on the development and production of complex organic molecules used in the synthesis of active pharmaceutical ingredients and agrochemicals. Its core competencies include a wide range of chemical reactions such as nitration, reduction, and chlorination, supported by robust research and development capabilities. Link Pharma Chem Ltd. serves a global clientele, providing custom synthesis and contract manufacturing services tailored to specific client requirements. The organization maintains a commitment to quality standards and process efficiency, ensuring the delivery of reliable chemical solutions for the life sciences and fine chemical sectors.

Recent filings

Filing Released Lang Actions
Newspaper Publication of Audited Financial Result of the Company for the Quarter and year ended 31st March, 2026. Published on 23rd May, 2026 in Business Standard (English Edition) and ....
Report Publication Announcement Classification · 70% confidence The document is a short notice addressed to the stock exchange under SEBI LODR Regulation 47(3), enclosing copies of newspaper advertisements for the extract of audited financial results for the quarter and year ended 31 March 2026. It does not itself contain financial data or constitute the full report; it simply announces and provides proof of publication of the results. This fits the “Report Publication Announcement” (RPA) category rather than an actual earnings release or full report.
2026-05-23 English
Non-Applicability of Regulation 24A of SEBI (LODR) Regulations, 2015 for Non submission of Annual Secretarial Compliance Certificate for year ended 31st March, 2026.
Regulatory Filings Classification · 65% confidence The document is a compliance letter submitted to BSE under SEBI (LODR) stating non-applicability of specific corporate governance provisions. It contains no financial statements, no link to an attached report, and is clearly a regulatory announcement. It does not fit any other specialized category, so it defaults to a general regulatory filing.
2026-05-21 English
Non Applicability of Regulations 23(9) of SEBI (LODR) Regulations 2015 on Disclosure of Non Applicability of reporting of Related Party Transactions for the Half year ended on 31st March, 2026.
Regulatory Filings Classification · 87% confidence The document is a letter addressed to BSE Limited indicating the non-applicability of certain SEBI (LODR) regulations for related party transaction disclosures. It does not contain actual financial statements, transaction details, vote results, or interim report data, nor is it a presentation or dividend notice. It is a compliance/regulatory announcement to the exchange, fitting the fallback category for miscellaneous regulatory filings. Therefore, it should be classified as Regulatory Filings (RNS).
2026-05-21 English
Re-appointment of Mr. Rishikesh S. Thakur as Managing Director of the Company for 3 years.
Board/Management Information Classification · 97% confidence The document is an official SEBI Reg.30 intimation to the stock exchange announcing the re-appointment of the Managing Director (a senior management change) and includes the required disclosures under Listing Regulations. This fits the “Board/Management Information” category (MANG).
2026-05-21 English
Re-appointment of Mr. Satish G. Thakur as Whole time Director for 3 years.
Board/Management Information Classification · 95% confidence The document is a formal disclosure under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements regarding the re-appointment of Mr. Satish G. Thakur as Chairman and Whole-time Director. It announces a change in the company’s board/senior management. This falls squarely under Board/Management Information (MANG).
2026-05-21 English
Audited Financial Results for the Quarter and year ended 31st March, 2026 along with Statutory Auditor''s Repot thereon.
Interim / Quarterly Report Classification · 85% confidence The document is an outcome of the board meeting under SEBI LODR Reg. 30 & 33 containing the full audited quarterly and year-end financial results of Link Pharma Chem Ltd., complete with statements of profit & loss, assets & liabilities, cash flows and the independent auditor’s report. It is not a brief highlights-only earnings release nor the full annual report; it is the statutory periodic financial report filed for the quarter and year. This aligns with our definition of an Interim/Quarterly Report. FY 2026
2026-05-21 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.